Salud financiera de hoja de balance de Boston Scientific
Salud financiera controles de criterios 4/6
Boston Scientific tiene unos fondos propios totales de $19.1B y una deuda total de $8.9B, lo que sitúa su ratio deuda/fondos propios en 46.5%. Sus activos y pasivos totales son $34.0B y $14.9B respectivamente. Boston Scientific El EBIT de la empresa es de $2.3B, por lo que su ratio de cobertura de intereses es de 9.2. Su tesorería e inversiones a corto plazo ascienden a $952.0M.
Información clave
46.6%
Ratio deuda-patrimonio
US$9.10b
Deuda
| Ratio de cobertura de intereses | 9.9x |
| Efectivo | US$865.00m |
| Patrimonio | US$19.53b |
| Total pasivo | US$15.61b |
| Activos totales | US$35.14b |
Actualizaciones recientes sobre salud financiera
Is Boston Scientific (NYSE:BSX) A Risky Investment?
Feb 02
Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Nov 03Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly
Jul 25Here's Why Boston Scientific (NYSE:BSX) Can Manage Its Debt Responsibly
Apr 18Recent updates
Boston Scientific: Implications Of The Axonics-Medtronic Patent Clash
Apr 05A Look At The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Mar 26We Ran A Stock Scan For Earnings Growth And Boston Scientific (NYSE:BSX) Passed With Ease
Feb 29What You Can Learn From Boston Scientific Corporation's (NYSE:BSX) P/E
Feb 15Is Boston Scientific (NYSE:BSX) A Risky Investment?
Feb 02Boston Scientific (NYSE:BSX) Could Be Struggling To Allocate Capital
Jan 19Boston Scientific: Portfolio Updates Driving Top-Line Growth
Jan 17Boston Scientific: Continued M&A Drives More Growth
Jan 10Is Boston Scientific Corporation (NYSE:BSX) Worth US$56.1 Based On Its Intrinsic Value?
Dec 04Does Boston Scientific (NYSE:BSX) Have A Healthy Balance Sheet?
Nov 03Boston Scientific: Delivering Strong Growth, But Sector Derating Is A Big Issue
Oct 30ADVENT Offers Up An Early Present For Boston Scientific Investors
Aug 28Estimating The Fair Value Of Boston Scientific Corporation (NYSE:BSX)
Aug 24Boston Scientific (NYSE:BSX) Seems To Use Debt Quite Sensibly
Jul 25Boston Scientific Remains Operationally Sound But May Have Limited Upside
Jul 14Investors Could Be Concerned With Boston Scientific's (NYSE:BSX) Returns On Capital
Jul 10Boston Scientific Corporation (NYSE:BSX) Shares Could Be 29% Above Their Intrinsic Value Estimate
May 21Here's Why Boston Scientific (NYSE:BSX) Can Manage Its Debt Responsibly
Apr 18Returns On Capital At Boston Scientific (NYSE:BSX) Paint A Concerning Picture
Apr 03Boston Scientific Stands Out With Strong, Diversified Growth Profile
Feb 15Boston Scientific Non-GAAP EPS of $0.45 misses by $0.02, revenue of $3.24B in-line
Feb 01Boston Scientific sees double digit EPS growth in 2023 - JPMorgan Healthcare conference
Jan 11Boston Scientific to acquire majority stake of Acotec Scientific
Dec 12Análisis de la situación financiera
Pasivos a corto plazo: BSXLos activos a corto plazo ($6.5B) de la empresa superan a sus pasivos a corto plazo ($4.6B).
Pasivo a largo plazo: Los activos a corto plazo de BSX ($6.5B) no cubren sus pasivos a largo plazo ($10.3B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: La relación deuda neta-capital de BSX (41.5%) se considera alta.
Reducción de la deuda: BSX ha pasado de 79.8% a 46.5% en los últimos 5 años.
Cobertura de la deuda: BSXLa deuda de la empresa está bien cubierta por el flujo de caja operativo (26.5%).
Cobertura de intereses: BSXLos pagos de intereses de su deuda están bien cubiertos por el EBIT (9.6x cobertura).